[
    "{\"step_by_step_thinking\": \"Enasidenib is a medication that belongs to a class of drugs called IDH inhibitors. It is specifically approved by the FDA for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Therefore, enasidenib can be used for the treatment of acute myeloid leukemia with an IDH2 mutation.\", \"answer_choice\": \"A. yes\"}"
]